Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AERI

Aerie Pharmaceuticals (AERI) Stock Price, News & Analysis

Aerie Pharmaceuticals logo

About Aerie Pharmaceuticals Stock (NASDAQ:AERI)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$15.25
$15.25
50-Day Range
$15.18
$15.25
52-Week Range
$4.81
$15.37
Volume
600 shs
Average Volume
974,748 shs
Market Capitalization
$753.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Remove Ads

Aerie Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
9th Percentile Overall Score

AERI MarketRank™: 

Aerie Pharmaceuticals scored higher than 9% of companies evaluated by MarketBeat, and ranked 921st out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Aerie Pharmaceuticals.

  • Earnings Growth

    Earnings for Aerie Pharmaceuticals are expected to grow in the coming year, from ($2.02) to ($1.18) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aerie Pharmaceuticals is -19.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aerie Pharmaceuticals is -19.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for AERI.
  • Dividend Yield

    Aerie Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Aerie Pharmaceuticals does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for AERI.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Aerie Pharmaceuticals this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Aerie Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.44% of the stock of Aerie Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    95.94% of the stock of Aerie Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Aerie Pharmaceuticals' insider trading history.
Receive AERI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerie Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AERI Stock News Headlines

Trump’s Treasure Map [Pic inside]
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
20 Countries With Worst Vision Problems
See More Headlines

AERI Stock Analysis - Frequently Asked Questions

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) released its earnings results on Thursday, November, 4th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.62) by $0.10. The company had revenue of $29.31 million for the quarter, compared to analysts' expectations of $29.13 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aerie Pharmaceuticals investors own include Canopy Growth (CGC), Nicox (NICXF), Bristol-Myers Squibb (BMY), Meta Platforms (META), NVIDIA (NVDA), Pfizer (PFE) and Melinta Therapeutics (MLNT).

Company Calendar

Last Earnings
11/04/2021
Today
3/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AERI
Employees
376
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-74,810,000.00
Pretax Margin
-16.47%

Debt

Sales & Book Value

Annual Sales
$194.13 million
Price / Cash Flow
N/A
Book Value
($3.32) per share
Price / Book
-4.59

Miscellaneous

Free Float
47,223,000
Market Cap
$753.61 million
Optionable
Optionable
Beta
-0.06

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

This page (NASDAQ:AERI) was last updated on 3/28/2025 by MarketBeat.com Staff
From Our Partners